Contribute Try STAT+ Today

Families and advocacy groups from dozens of countries around the world are urging Vertex Pharmaceuticals (VRTX) to take several steps to widen global access to its cystic fibrosis medicines and avoid “fatal inequality.”

In an open letter, they suggested providing the drugs at affordable prices, offering the medicines on a so-called compassionate use basis where the drugs are not yet available, or issuing licenses to generic makers in countries where the company does not plan to supply the treatments any time soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.